WEBINARS AND EVENTS Updates to Cancer Risk and Clinical Guidance for Germline Variation in CHEK2 Speakers: Irene Rainville MS, PhD, LCGC Erin Mundt MS, LCGC Date: 02/27/2024 Duration: 1 hour CEU: No This program provides a summary of recent literature related to CHEK2-associated cancer risks and management implications. Our speakers will evaluate current evidence that compares the cancer risks associated with different types of germline CHEK2 variants. Identify challenges of CHEK2 variant classification as reviewed in recent clinical practice guidelines. Define evidence for cancer risk associated with germline pathogenic variants (PV) in CHEK2. Examine management implications for CHEK2-associated cancer risks. Summarize recent evidence comparing cancer risks between individuals with different types of germline CHEK2 variants. Hear from our Speakers Irene Rainville MS, PhD, LCGC Irene Rainville is a genetic counselor with the Medical Information Liaison Team at Myriad Laboratories. She currently has an interest in the moderate-risk breast cancer genes and tracks literature and clinical management for inherited cancer risk related to ATM, CHEK2 and PALB2. Erin Mundt MS, LCGC Erin Mundt is the director of Clinical Genomics at Myriad Genetics. In this role, Erin specializes in oncology variant classification. She has been a member of the classification team at Myriad for almost 10 years. Erin has authored a number of publications on complexities of variant classification, including two on CHEK2 specifically.